- Proceeds dedicated to advance Herpes simplex treatment IM-250 to Phase II
- IM-250 demonstrates unprecedented impact on viral reservoir in preclinical studies
Munich, Germany, June 9, 2021 - LSP, one of Europe’s leading life sciences and healthcare investors, today announced its investment in Innovative Molecules GmbH, a German, Munich-based drug development company. Innovative Molecules is focused on developing next-generation treatments for Herpes simplex-induced diseases. The € 20 million Series A equity financing round was led by LSP, investing from its LSP 6 fund.
The company will use the funds to advance its preclinical product candidate, IM-250, from the current late preclinical stage to a Phase 2 proof-of-concept study.
IM-250 is a potent inhibitor of Herpes Simplex Virus type 1 (HSV-1) and type 2 (HSV-2) replication. The compound targets the helicase-primase enzyme complex of the virus. Due to its demonstrated impact on the viral reservoir in preclinical studies, IM-250 may become a game-changer for the treatment of HSV-related diseases due to its potential to alter the natural course of the disease.
Gerald Kleymann, founder & Chief Executive Officer at Innovative Molecules, comments: ”Within the last 25 years the treatment of Herpes simplex has not seen an innovation that managed to reach the market. Our ambition is to change this. With IM-250 we will alter the way Herpes is treated. Our goal is to reduce or even eradicate the reservoir of the virus in order to achieve long-lasting effects, less recurrences and real benefits for patients.“
Joachim Rothe, Managing Partner at LSP, complements: ”I am pleased with LSP leading the investment syndicate of Innovative Molecules. There is an urgent medical need in Herpes-induced diseases. Current treatments have minimal efficacy and cannot change the persistence of the infection. Moreover, resistance to today’s standard treatments occur quite often and can lead to life-threatening complications or even to the death of patients.“
Thomas Hoffmann, co-founder & financial advisor to Innovative Molecules, states: “To have gained LSP as one of the leading European life sciences funds as the lead investor for this Series A financing round is truly a quality stamp for our project. We are looking forward to working together with LSP on this exciting drug development opportunity.“
« back to overview